We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Michele Trott, PhD

Michele Trott, PhD

Contact Us

Michele Trott (nee Wilson) is a New Zealand-based science writer who pursues freelance writing projects alongside her in-house role as a scientific content writer at Izon Science. After completing her PhD (Endocrinology) at Lincoln University (NZ), Michele began pursuing her science writing career with Technology Networks in the UK. There, she spent 12 months covering a maternity leave role as a science editor, and managed the cell science, biopharma and diagnostics communities. Upon her arrival back in NZ, Michele established “Choice Science Writing” and became a full-time freelance science writer, working with life science marketing agencies, biotech companies – and of course, Technology Networks – to produce engaging articles and blog posts. In April 2021, she took up the opportunity to join the team at Izon Science, a company that enables the precise separation and analysis of extracellular vesicles and other nanoparticles.


Latest Content
Talking NGS, Liquid Biopsies and Tumor Mutational Burden With Luca Quagliata
Industry Insight

Talking NGS, Liquid Biopsies and Tumor Mutational Burden With Luca Quagliata

We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.
App Alerts Hospital Staff to Potentially Fatal Kidney Condition in Minutes
News

App Alerts Hospital Staff to Potentially Fatal Kidney Condition in Minutes

A mobile phone app has been developed to inform doctors and nurses of patients with acute kidney injury, a potentially fatal condition. The app reduces the time it takes for hospital staff to become aware of critical blood test results, from hours to minutes.
Imagine Collaboration, Without the Faff
Industry Insight

Imagine Collaboration, Without the Faff

Imagine if there was a better way to write, format, and review scientific manuscripts for publication. doDOC Document Collaboration Expert Leif Måsvær believes there is. Leif explains how this cloud-based platform is a game-changer that overcomes the major obstacles present during the authoring, writing, and reviewing process.
Leading Minds Reflect On How the World Feels About Science and Health
Article

Leading Minds Reflect On How the World Feels About Science and Health

Gauging global attitudes to science and health is no easy task, but it was the goal of The Wellcome Global Monitor – a survey of over 140,000 people aged 15 and older, from more than 140 countries. The findings present an unprecedented view of the relationship between science and society worldwide, which were discussed by leaders at the launch event in Washington D.C.
Zika vs Dengue: Minimizing Cross-reactivity in Immunoassay Development
Industry Insight

Zika vs Dengue: Minimizing Cross-reactivity in Immunoassay Development

The Zika virus poses a significant global risk, and there is currently no vaccine or specific treatment available for those infected. Having access to sensitive and specific diagnostic assays is essential to disease management, and in enabling effective research and the development of therapeutics. We spoke to Nick Roesen, Founder and COO of The Native Antigen Company, to learn about the Zika virus immunoassays that have been developed to overcome cross-reactivity with Dengue.
Authors' Perspectives: Cell Size Sparks Embryonic Genome Awakening
Article

Authors' Perspectives: Cell Size Sparks Embryonic Genome Awakening

At some point in the early life of an embryo, zygotic nuclei "wake up" and take control of subsequent embryo development. As featured on the cover of Developmental Cell, a new study provides evidence supporting the hypothesis that cell size is the principal determinant of this transition from maternal to embryonic control. We spoke to a few of the co-authors to learn more about this important finding.
Colorectal Cancer Blood Test Driven by Immuno-transcriptomics
Industry Insight

Colorectal Cancer Blood Test Driven by Immuno-transcriptomics

By studying gene expression modifications induced by the immune response, Novigenix has developed a blood test for colorectal cancer. This Q&A with Jan Groen, CEO, provides insights on the test, and on the field of study that could revolutionize cancer diagnosis.
World’s First Reported Spontaneous Clearance of HIV, Without Treatment
News

World’s First Reported Spontaneous Clearance of HIV, Without Treatment

In 1981, a patient from Sydney was transfused with a weakened form of HIV-1 when he received a blood transfusion following a motorbike accident. After controlling his infection for more than 30 years, he appears to have cleared his infection altogether – without therapy.
Anti-influenza Agents Inspired by Immunotherapy
Industry Insight

Anti-influenza Agents Inspired by Immunotherapy

Given the urgent need for compounds that can effectively prevent and treat influenza, San Diego-based Cidara Therapeutics are working to develop antiviral conjugates. We spoke to Les Tari, Senior VP of Research, to find out about their unique approach and lead candidate.
Why Should Antibodies Be Manufactured Recombinantly?
Industry Insight

Why Should Antibodies Be Manufactured Recombinantly?

Given that bad antibodies are likely to blame for a significant proportion of the reproducibility crisis in science, any efforts to reduce batch-to-batch variability are more than welcome. One company with a plan to help in this area is “Absolute Antibody”, who believe that recombinant antibodies are the way forward. To learn more about making antibodies with recombinant technology, we spoke to Ian Wilkinson, PhD, Chief Scientific Officer.
Advertisement